Axsome Therapeutics (AXSM) is down about 3.52% to $182.27 in Tuesday trading (April 21, 2026), as the stock gives back some gains amid positioning ahead of a key FDA catalyst. The next major event investors are focused on is the April 30, 2026 PDUFA target action date for AXS-05 (dextromethorphan-bupropion) for agitation associated with Alzheimer’s disease, following the FDA’s acceptance of the supplemental NDA under Priority Review.

No fresh headline item appeared to be driving the move, increasing the odds that today’s decline reflects routine de-risking and profit-taking as traders manage exposure into binary regulatory outcomes. With the decision date now close, short-term holders often reduce risk or rebalance positions, which can pressure shares even when the longer-term thesis remains unchanged.

The April 30, 2026 FDA decision is the near-term center of gravity for the stock, and volatility can rise as the date approaches. Investors are also looking toward Axsome’s next earnings print (widely tracked for early May) as a secondary catalyst to reassess commercial momentum in the company’s marketed CNS portfolio and spending trajectory.